semaglutide fda approval mash Approves for with Moderate-to-Advanced Fibrosis | Yuki Sakakibara posted on the topic Semaglutide FDA Approved MASH Treatment

El ensayo clnico de fase 3 ACHIEVE-3 es un estudio pionero, ya que el GLP-1 oral de Lilly ha superado a otro tratamiento GLP-1 oral tanto en los objetivos primarios como en todos los objetivos secundarios clave

A 12-week trial at 1.0mg showed semaglutide reduced energy intake by approximately 35% versus placebo

Lillys phase 2 retatrutide trial achieved up to 17.5% mean weight reduction at 24 weeks

Adults taking tirzepatide had a mean reduction in waist circumference of 18.4 cm (7.2 in) compared to 13 cm (5.1 in) for those on semaglutide

These effects relate to minoxidils original blood pressure-lowering mechanism

Those with type 2 diabetes are at a significantly higher risk of cardiovascular disease because they may develop high blood pressure, high cholesterol, or both, as a result of uncontrolled blood sugar